Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 4, 2002, Pages 266-270

  Nomata, Koichiro ^a   Noguchi, Mitsuru ^a   Kanetake, Hiroshi ^a   Tsuda, Nobuo ^a   Hayashi, Mikio ^b   Yamashita, Shuji ^c   Sakuragi, Tsutomu ^d   Kusaba, Yasuyuki ^e   Shindo, Kazuhiko ^f  

^a NAGASAKI UNIVERSITY   (Japan)

^b Department of Urology   (Japan)

^c Kohseikai Hospital   (Japan)

^d Nagasaki Municipal Hospital   (Japan)

^e Japanese Red Cross Nagasaki Atomic Bomb Hospital   (Japan)

^f Ureshino Medical Center   (Japan)

Author keywords

Epirubicin; Intravesical chemotherapy; Maintenance; Superficial bladder cancer

Indexed keywords

EPIRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PREVENTION; CANCER RECURRENCE; CANCER SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; LONG-TERM CARE; MALE; URINARY BLADDER NEOPLASMS;

EID: 0036390050     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0487-6     Document Type: Article

References (21)

1. Ali-El-Dein B, El-Baz M, Aly NM, Shamaa S, Ashamallah A (1997) Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 158:68
2. Au JL-S, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597
3. Bonfante V, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68:105
4. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger DB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional organization for research and treatment of cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 153:934
5. Cookson MS, Sarosdy MF (1995) Management of stage T1 superficial bladder cancer with intravesical Bacillus Calmette-Guérin therapy. J Urol 148:797
6. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasma of the urinary bladder. Am J Surg Pathol 22:1435
7. Herr HW, Laudone YP, Whitmore WF Jr (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138:1363
8. Hinotsu S, Akaza H, Ohashi Y, Kotake T (1999) Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection. A combined analysis of trials by Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86:1818
9. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL (2001) Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165:1124
10. Lamm DL (1995) BCG immunotherapy for transitional-cell carcinoma in situ of the urinary bladder. Oncology 9:947
11. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163:1124
12. Lum BL, Torti FM (1991) Adjuvant intravesical pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst 83:682
13. Messing EM, Catalona W (1998) Natural history in bladder cancer. In: Walsh PC, Retic AB, Vaughan ED, Wein AJ (eds) Campbell's urology. W.B. Saunders, Philadelphia, p 2348
14. Mostofi FK, Sorbin LH, Torloni H (1973) Histological typing of urinary bladder tumours (international histological typing of urinary bladder tumors, no. 10), World Health Organization, Geneva
15. Okamura K, Murase T, Obata K, Ohshima S, Ono Y, Sakata T, Hasegawa Y, Shimoji T, Miyake K (1994) A randomized trial of early intravesical instillation of epiadria in superficial cancer. Cancer Chemother Pharmacol [Suppl] 35:S31
16. Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi M, Fukatsu T, Ohshima S (1998) A randomized study of short- versus long-term intravesical epirubicin instillation for superficial bladder cancer. Eur Urol 33:285
17. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Syvester R (1993) A prospective European Organization for Research and Treatment of Cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749
18. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, Vander Meijden A, Parmar MK, Bijnens L (1996) A combined analysis of European Organization for Research and Treatment of Cancer and medical research council randomized clinical trials for the prophylactic treatment of stage Ta/T1 bladder cancer. J Urol 156:1934
19. Rajala P, Liukkonen T, Raitanen M, Rintala E, Kaasinen E, Helle M, Lukkarinen O, The Finnbladder group (1999) Transurethral resection with perioperative instillation of interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multi-center study - Finnbladder III. J Urol 161:1133
20. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG (1999) Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and TIS). J Urol 162:1697
21. Tolley DA, Hargreave TB, Smith PH, Williams JL, Grigor KM, Parmar MK, Freedman LS, Uscinska BM (1988) Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). BMJ 296:1759